Gasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI

Authors

DOI:

https://doi.org/10.33448/rsd-v10i5.14726

Keywords:

Enzyme replacement therapy; Galsulfase; Leukocyte inclusions; Lysosomal storage disease; Mucopolysaccharidosis type VI.

Abstract

The mucopolysaccharidosis (MPS) type VI is a rare lysosomal storage disease presenting leukocyte inclusions (Alder-Reilly anomaly) and lymphocytes with metachromatic inclusion surrounded by clear spaces, Gasser cells. Currently, an enzyme replacement therapy (ERT) with galsulfase is used to treat MPS type VI. This study evaluated 14 patients with MPS type VI performed cell counts Gasser before and after six months from the beginning of ERT. It was observed an average of 12.7% cells per patient, and after six months was found complete cell Gasser disappearance, proving to be an effective biomarker of response to ERT.

References

Aerts J. M. F. G., Kallemeijn W. W., & Wegdam W. (2011). Biomarkers in the diagnosis of lysosomal storage disorders; proteins, and antibodies. J. Inherit Metab Dis, 34, 6005-19.

Cardoso-Santos A., Azevedo A. C., Fagondes S., Burin M. G., Giugliani R., & Schwartz I. V. (2008). Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Assessment of joint mobility and grip and pinch strength. J. Pediatr,. 84,130-135.

Concolino, D., Deodato, F., & Parini, R. (2018). Enzyme replacement therapy: Efficacy and limitations. Italian Journal of Pediatrics, 44(Suppl 2).

Di Natale P., Villani G. R., Parini R., Scarpa M., Perenti G., Pontarelli G., Grosso M., Sersale G., Tomanin R., Sibilio M., Barone R., Filmara A. (2008). Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. Biotechnol Appl Biochem, 49, 219-223.

Fenneteau O. (2011). Anomalías morfológicas de los leucócitos en el niño. Acta bioquímica clínica latinoam. 43, 667-677.

Giugliani R., Harmatz P., & Wraith J. E. (2007). Management guidelines for mucopolysaccharidosis VI. Pediatrics, 120, 405-18.

Khan, S. A., Mason, R. W., Giugliani, R., Orii, K., Fukao, T., Suzuki, Y., Yamaguchi, S., Kobayashi, H., Orii, T., & Tomatsu, S. (2018). Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Molecular Genetics and Metabolism, 125(1–2), 44–52.

Khan, S. A., Peracha, H., Ballhausen, D., Wiesbauer, A., Rohrbach, M., Gautschi, M., Mason, R. W., Giugliani, R., Suzuki, Y., Orii, K. E., Orii, T., & Tomatsu, S. (2017). Epidemiology of mucopolysaccharidoses. Molecular Genetics and Metabolism, 121(3), 227–240.

Kubaski, F., De Oliveira Poswar, F., Michelin-Tirelli, K., Burin, M. G., Rojas-Málaga, D., Brusius-Facchin, A. C., Leistner-Segal, S., & Giugliani, R. (2020). Diagnosis of mucopolysaccharidoses. Diagnostics, 10(3).

Harmatz P., Giugliani R., Schwartz I. V. D., Guffon N., Teles L. T., Miranda M. C. S., Wraith E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J. J., Plecko B., Steiner R., Whitley C. B., & Decker C. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of thee clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab, 94, 469-475.

Harmatz, P. R., Lampe, C., Parini, R., Sharma, R., Teles, E. L., Johnson, J., Sivam, D., & Sisic, Z. (2019). Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program. Journal of Inherited Metabolic Disease, 42(3), 519–526.

Harmatz, P. R., & Shediac, R. (2017). Mucopolysaccharidosis VI: Pathophysiology, diagnosis and treatment. Frontiers in Bioscience - Landmark, 22(3), 385–406.

Heron D., Baumann C., & Benichou J. (2004). Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur. J. Pediatr, 163,323-326.

Hochman, B., Nahas, F. X., Filho, R. S. de O., & Ferreira, L. M. (2005). Research designs. Acta Cirúrgica Brasileira, 20(2), 02–09.

Honjo, R. S., Vaca, E. C. N., Leal, G. N., Abellan, D. M., Ikari, N. M., Jatene, M. B., Martins, A. M., & Kim, C. A. (2020). Mucopolysaccharidosis type VI: Case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation. BMC Medical Genetics, 21(1), 1–8.

Langford-Smith K. J., Mercer J., Petty J., Tylee K., Church H., Roberts J., Moss G., Jones S., Wynn R., Wraith J. E., & Bigger B. W. (2011). Heparin cofactor II-thrombin complex and dermatan sulfate: chondroitin sulphate ratio are biomarkers of short-and long-term treatment effects in mucopolysaccharide diseases. J. Inherit Metab Dis, 34, 499-508.

Rovelli A. M. (2008). The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone marrow Transplant., 41, 87-89.

Swiedler S., Beck M., & Bajbouj M. (2005). Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A., 150, 134:144.

Tessitore A., Pirozzi M., & Auricchio A. (2009). Abnormal autoplagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics, 4, 2009. June 16.

Tomanin, R., Karageorgos, L., Zanetti, A., Al-Sayed, M., Bailey, M., Miller, N., Sakuraba, H., & Hopwood, J. J. (2018). Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene. Human Mutation, 39(12), 1788–1802.

Turbeville S., Nicely H., Rizzo J., Pedersen T. L., Orchard P. J., Horwitz M. E., Horwitz E. M., Veys P., Bonfim C., & Al-Seraihy A. (2011). Clinical outcome following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Molecular genetics and metabolism, 102,111-115.

Valayannopoulos, V., Nicely, H., Harmatz, P., & Turbeville, S. (2010). Mucopolisaccharidosis VI. Orphanet J. Rare Dis, 5, 1-20.

Villani G. R. D., Grosso M, Pontarelli G., Chierchia A., Sessa R., Sibilio M., Parenti G., & Di Natali P. (2010). Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient. Genetic testing and molecular biomarkers, 14,113-20.

Downloads

Published

05/05/2021

How to Cite

MELO, M. A. W. de; KERTENETZKY, M. S. .; SILVEIRA , C. M. da; RIBEIRO, M. M.; ARCANJO, G. da S.; LUCENA-ARAÚJO, A. R.; BEZERRA, M. A. C.; MUNIZ, M. T. C.; CAVALCANTI, M. do S. de M. Gasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI. Research, Society and Development, [S. l.], v. 10, n. 5, p. e24510514726, 2021. DOI: 10.33448/rsd-v10i5.14726. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/14726. Acesso em: 29 jan. 2023.

Issue

Section

Health Sciences